Padilla-Padilla F, Reyes F, Ariza H, Montoya A, Ledesma M, Escudero X, Palomo A, Astudillo R, Abundes A, Flores J, Estrada J, Farell-Campa J

Idioma: Español
Referencias bibliográficas: 42
Paginas: 111 - 117
Archivo PDF: 86.09 Kb.

RESUMEN

Introducción: la trombosis es importante en la oclusión aguda de stents intracoronarios. Las heparinas de bajo peso molecular (HBPM) como nadroparina cálcica aventaja a la heparina no fraccionada (HNF) en prevención de eventos trombóticos. El objetivo del estudio fue comparar eficacia en prevención de trombosis u oclusión aguda de stents en intervención coronaria percutánea (ICP) entre nadroparina cálcica y HNF. Material y métodos: en un estudio prospectivo, aleatorizado y ciego simple; realizamos ICP + Stent electiva en 38 pacientes, tratados al azar con 86 UI AXa/kg de nadroparina o 70 UI/kg de HNF durante la ICP. La evaluación estadística fue con medias, desviaciones estándar, Chi-cuadrada, prueba exacta de Fisher y t de Student. Resultados: asignados al azar 18 pacientes a nadroparina y 20 a HNF encontrando una menor incidencia de infarto del miocardio de 0 vs 10% (p = 0.270), oclusión aguda de stent (5.6% vs 10% p = 0.541) y complicaciones hemorrágicas (0 vs 10% p = 0.270) en los pacientes con nadroparina que en los pacientes con HNF posterior a la ICP; pero no en mortalidad (nadroparina 5.6% vs HNF 0% p = 0.474). Conclusiones: la utilización de nadroparina cálcica fue similar en seguridad y eficacia que HNF como tratamiento adyuvante en pacientes con ICP + Stent.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Noble S, Spencer C. Enoxaparin. A review of its clinical potential in the management of coronary artery disease. Drugs 1998; 56(2): 259-272.

2. Fox K. Low molecular weight heparins in acute coronary syndromes. Eur Heart J 1998; 19: 817-819.

3. Preisack M, Bonan R, Meisner C. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. Eur Heart J 1998; 19: 1232-1238.

4. Rutsch W, Baumann G. Anticoagulation in interventional cardiology optimizing patient outcome. Eur Heart J 1998; 19(Suppl. K): K11-K17.

5. Garachemani A, Meier B. Heparin for coronary angioplasty: high dose, low dose, or no dose? Heart 1998; 80: 3-4.

6. Ragosta M, Karve M, Brezynski D. Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention. Am Heart J 1999; 137: 250-257.

7. Matthai W, Kurnik P, Groh W. Antithrombin activity during the period of percutaneous coronary revascularization. JACC 1999; 33: 1248-56.

8. Bertrand M, Rupprecht H, Urban P. Double-blind study of the safety of clopidogrel with and without loading dose in combination with aspirin after coronary stenting. CLASSICS. Circulation 2000; 102: 624-629.

9. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? JACC 2000; 35(7): 1699-712.

10. Shaknovich A. Complications of coronary stenting. Coronary Artery Dis 1994; 5: 583-589.

11. Roubin G, Cannon A, Agrawal S. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992; 85: 916-927.

12. George B, Voorhees W, Roubin G. Multicenter investigation of coronary stenting to treat acute or threatened closure complicating percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. JACC 1993; 22: 135-143.

13. Topol E. Caveats about elective coronary stenting. N Engl J Med 1994; 331: 539-541.

14. Schömig A, Neummann F, Kastrati A. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary Stents. N Engl J Med 1996; 334: 1084-1089.

15. Bertrand M, Legrand V, Boland J. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998; 98: 1597-1603.

16. Leon M, Baim D, Popma J. A clinical trial comparing 3 antithrombotic drug regimens after coronary artery stenting. N Engl J Med 1998; 339: 1665-1671.

17. Urban P, Macaya C, Rupprecht H. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high risk patients. Circulation 1998; 98: 2126-2132.

18. Herbert J, Frehel D, Valle E. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198.

19. CAPRIE Steering committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.

20. Harker L, Marzec U, Kelly A. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998; 22: 2461-2469.

21. Makkar R, Eigler S, Kaul S. Effects of clopidogrel, aspirin, and combined therapy in a porcine exvivo model of high shear induced stent thrombosis. Eur Heart J 1998; 19: 1538-1546.

22. Turpie A. Can we differentiate the low molecular weight heparins? Clin Cardiol 2000; 23(Suppl. 1): 14-17.

23. The Frax I.S. group study. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6 days treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. Eur Heart J 1999; 20(21): 1553-1562.

24. Antman E, Radley D, Cohen M. Assessment of the treatment effect of enoxaparin for unstable angina/ non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100(15): 1602-8.

25. Zed P, Tisdale J, Borzak, E. Low molecular weight heparins in the management of acute coronary syndromes. Arch Intern Med 1999; 159(16): 1849-57.

26. Winter R, Levi M, Adams R. Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam. Heart 1998; 80(1): 35-9.

27. Mark D, Cowper P, Berkowitz S. Economic analysis of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998; 97: 1702-7.

28. Cohen M, Demers C, Gurfinkel E. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease (ESSENCE trial). N Engl J Med 1997; 337: 447-52.

29. Serruys P, Herrman J, Simon R. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. HELVETICA Investigators. N Engl J Med 1995; 333: 757-63.

30. The EPIC investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.

31. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.

32. The EPILOG investigators. Platelet Glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.

33. Karsch K. Low molecular weight heparin in prevention of restenosis after PTCA, the REDUCE trial. JACC 1996; 28: 1437-43.

34. Cairns J, Gill J, Morton B. EMPAR collaborators. Fish oils and low molecular weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR study. Circulation 1996; 94: 1553-60.

35. Faxon D, Spiro T, Minor S. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994; 90: 908-14. 36.Lablanche J, McFadden E, Meneveau N. Effect of nadroparin, a low molecular weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty. The FACT study. Circulation 1997; 96: 3396-402.

36. Kruse K. Enoxaparin and Ticlopidine After Elective Stenting, the ENTICES trial. JACC 1997; 27: 34A.

37. Gasperetti C, Gonias S, Gimple L. Platelet activation During coronary angioplasty in humans. Circulation 1993; 88: 2728-34.

38. Lincoff A, Popma J, Ellis S. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic, and therapeutic profile. JACC 1992; 19: 926-35.

39. Wilcox J. Thrombin and other potential mechanisms underlying restenosis. Circulation 1991; 84: 432-5.

40. Bittl J, Strony J, Brionker J. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-9.

41. Antman E, McCabe C, Gurfinkel E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Qwave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI ) 11B trial. Circulation 1999; 100: 1593-1601.

42. Hanke H, Oberhoff M, Hanke S. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular weight heparin. Circulation 1992; 85: 1548-1556.